Mar 19, 2008 | EMaxHealth
Femara Cuts Breast Cancer Repetition Risk
“The risk that hormone-dependent breast cancer will recur continues indefinitely, and our results imply that aromatase inhibition is effective whenever initiated”
Women taking Femara have lower risk for breast cancer repetition. Women surviving breast cancer by taking surgery, radiation and chemotherapy are facing the risk for cancer repetition after a few years after ... via EMaxHealth
Comment?
Femara, Letrozole Forum & PollsMar 17, 2008 | Cape Cod Times
Potential treatment could cut breast cancer recurrence risk
“Our results say that for the first time in the history of breast cancer, there is a treatment you can start - remote from a diagnosis - that can dramatically reduce the risk of a recurrence”
Women who survive breast cancer are often haunted by the fear that it might come back. via Cape Cod Times
Mar 15, 2008 | PharmaGossip
Cancer drug patents - Thai's stick
Thailand's Public Health Minister, Chaiya Sasomsap, is set to advise the government today that it should continue to override the patents on three cancer drug treatments - Novartis' Femara , Sanofi-Aventis' ... via PharmaGossip
Mar 13, 2008 | Science Daily
Late Treatment With Letrozole Can Reduce Breast Cancer Recurrence Risk
“It appears that estrogen-sensitive tumors remain hormone dependent and that patients' survival can be improved with careful use of aromatase inhibitors, even many years after completing tamoxifen treatment”
The results of a study involving women originally in the placebo arm of an international trial of letrozole will appear in the Journal of Clinical Oncology and are receiving early online release. via Science Daily
Mar 12, 2008 | CBC News
Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer
“The only imperfection of this trial, in terms of its design, is that it was not randomized - patients chose whether or not to continue on letrozole”
There's good news for the 60 percent of women with breast cancer whose malignancies are estrogen-driven: Researchers say taking the aromatase inhibitor drug letrozole can cut risk of a recurrence by more than ... via CBC News
Mar 11, 2008 | CBS13/CW31
Tamoxifen Alternative Can Be Taken Years Later
Researchers have found that women who've taken the breast cancer drug Tamoxifen can benefit by following it up with another drug, Femara - even if they start that second drug years later. via CBS13/CW31
Mar 11, 2008 | Medical News
Late treatment with letrozole (Femara) can reduce breast cancer recurrence risk
“These results can be put into practice right away to improve the outlook for women treated for receptor-positive breast cancer.”
Treatment with the aromatase inhibitor letrozole can reduce the risk of breast cancer recurrence even when initiated one to seven years after a course of tamoxifen therapy. via Medical News
Mar 3, 2008 | The National
No cancellation of CL for cancer drugs : Chaiya
“Some information and the process of the recent imposition of compulsory licensing for cancer drugs was not legal because it was not imposed by Cabinet resolution”
The Public Health Ministry will not revoke the recent enforcement of compulsory licensing for cancer drugs and will retain it as a key mechanism to negotiate with drug firms to reduce product prices, said ... via The National
Feb 29, 2008 | The National
Drugs licensing 'can save Bt8 bn'
The Public Health Ministry will soon be told the country can save as much as Bt8 billion from compulsory licensing of life-saving drugs. via The National
Jan 17, 2008 | Pravda
Novartis predicts good 2008 in spite of 4Q difficulties
By Alex Steblinina. Restructuring charges and the impact of generic competition led to sharp fall in 4-quarter profits of Novartis. via Pravda
Femara, Letrozole (generic) Editors
Romary59 is editing the Femara, Letrozole News page.
One big 
News Trends
Topix Quick Polls
